Whitepapers
Penetrating the CNS – Strategic Implications of an Increasingly Flexible FDA
Whitepaper
Nov 21, 2023
Half-time in the EU HTA Regulation Roll Out
Whitepaper
Sep 22, 2023
Before You Start the Strategic Planning Cycle: 5 essential things to streamline your approach
Whitepaper
Sep 11, 2023
ICER Value Assessment Framework Update 2023
How will the proposed updates to the ICER Value Assessment
Framework affect manufacturers preparing to launch products in the US? In this whitepaper, we present an overview of ICER’s work to date, highlighting key trends and providing insights into the impact of the coincidental timing between the ICER Value Assessment Framework update and new IRA process.
Whitepaper
Aug 31, 2023
Advancing Clinical Development by Strategically Leveraging Advisory Boards
Whitepaper
Aug 11, 2023
CAR T-Cell Therapies in the US, UK and EU4
Whitepaper
Aug 8, 2023
Making a Case for Using Real World Data to Model Patient Entry in Budget Impact Analyses
Whitepaper
Jul 13, 2023
A Practical Guide to Segmentation: What, who, why, and how?
Whitepaper
Jul 5, 2023
Scenario-based Strategy in Tumultuous Times: How pharma executives can conquer uncertainty
Whitepaper
Jun 28, 2023
Navigating New Competitive Crosswinds: How Pharma Can Plan for Success
Whitepaper
Jun 26, 2023
Opportunities for Enhanced Communication between Manufacturers and US Payers
In light of recent legislation we put Health Care Economic Information (HCEI) and Pre-approval Information Exchange (PIE) under the microscope. In the process we discuss effective strategies to drive collaborative discussions between manufacturers and payers
View
Jun 14, 2023